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A B S T R A C T
Background: Mutations of the NOD2 gene increase the
susceptibility of humans to Crohn’s disease. NOD2 is a
cytoplasmic receptor for the bacterial product peptidoglycan.
There is considerable controversy in the literature whether
the most common mutation in Crohn’s disease, the
3020insC NOD2, leads to a loss of function, i.e. decreased
cytokine production, or to the reverse, i.e. a gain of function.
In previous papers we proposed the former, since we could
show decreased cytokine production with a net proinflam-
matory status after exposure to muramyl dipeptide (MDP). 
Methods: Because of recent data in the literature showing
increased interleukin- (IL-1) production in mice with
the corresponding NOD2 mutation, we investigated the
production of this cytokine by cells of patients with
Crohn’s disease, either homozygous or heterozygous for
the 3020insC mutation, and compared it with that of
patients with Crohn’s disease bearing the wild-type allele. 
Results: A strongly decreased production of IL-1 by
peripheral mononuclear cells was found upon exposure
to either peptidoglycan or peptidoglycan-derived MDP in
homozygous patients bearing the 3020insC NOD2 mutation. 
Conclusion: This sustains the hypothesis that the
3020insC mutation in the human NOD2 gene leads to a
loss-of-function phenotype.
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In recent years, the insight into genetic susceptibility to
Crohn’s disease has greatly increased. A susceptibility
locus for Crohn’s disease was detected on chromosome
16,1 and subsequently the candidate NOD2 gene has been
identified as the susceptibility locus IBD1.2-4 NOD2 is a
member of the NOD-leucine-rich repeat (LRR) protein
family (also called the CATERPILLER family), known to
be involved in recognition of microbial structures, and is
expressed intracellularly in antigen-presenting cells.5
Initially, NOD2 was believed to be an intracellular pattern
recognition receptor for lipopolysaccharide (LPS),4 similar
to NOD1,6 but further investigations have demonstrated
that NOD2 is the intracellular receptor for the muramyl
dipeptide (MDP) component of bacterial peptidoglycan
(PGN).7,8
The mutated NOD2 associated with Crohn’s disease has
been reported to be unable to sense MDP and this would
suggest that the mutation would result in a loss-of-function
phenotype. This is consistent with the finding that
peripheral blood cells of patients with the NOD2 mutation
exposed to NOD2 ligands produce low amounts of the
proinflammatory cytokines tumour necrosis factor alpha
(TNF), interleukin-6 (IL-6) and IL-8, as well as the anti-
inflammatory cytokine IL-10.9,10 Conceptually this poses
an enigma, because Crohn’s disease is an inflammatory
disease. In essence, two basically opposite hypotheses
have been put forward: one advocating that the NOD2
mutation leads to defective anti-inflammatory control
(‘loss-of function’), the other advocating that the mutation
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leads to activated inflammation (‘gain of function’). So far,
we have been more in favour of the loss-of-function
hypothesis as we obtained experimental evidence for a
defective response to peptidoglycan and MDP in cells with
this mutation. Recently, however, Maeda et al. proposed a
gain-of-function effect of NOD2 mutations based on the
finding of greater IL-1 release in MDP-stimulated cells of
mice bearing an NOD2 mutation that corresponds to the
human 3020insC mutation. Prompted by the intriguing
findings of Maeda et al. on the increased IL-1 processing,
we measured mature IL-1 released by the mononuclear
cells of patients with the 3020insC mutation, after stimu-
lation with either peptidoglycan, or a combination of
MDP with the lipoprotein MALP-2, a Toll-like receptor-2
(TLR2) agonist. The latter stimulation was investigated,
because we recently demonstrated synergy between the
cell surface pattern recognition receptor TLR2 and the
cytoplasmic NOD2.11
M A T E R I A L S  A N D  M E T H O D S
Genotyping of NOD2 variants 
Blood was collected from 74 patients with Crohn’s disease
and ten healthy volunteers. Polymerase chain reaction
(PCR) amplification of NOD2 gene fragments containing
the polymorphic site 3020insC was performed in 50 l
reaction volumes containing 100 to 200 ng genomic DNA,
as previously described.10 The 3020insC polymorphism
was analysed by Genescan analysis on an ABI Prism
3100 Genetic Analyser according to the manufacturer’s
protocol (Applied Biosystems, Nieuwerkerk a/d IJssel,
the Netherlands). 
Four patients with Crohn’s disease were found homozygous
for the 3020insC mutation, and they were further investigat-
ed in the cytokine studies. As control groups, five patients
with Crohn’s disease heterozygous for the 3020insC NOD2
mutation, five patients with Crohn’s disease bearing the
wild-type allele, and five healthy volunteers homozygous
for the wild-type NOD2 allele were included.
Isolation of mononuclear cells and stimulation of
cytokine production
After obtaining informed consent, venous blood was drawn
from the cubital vein of patients and healthy volunteers
into three 10 ml EDTA tubes (Monoject, s-Hertogenbosch,
the Netherlands). The mononuclear cell (MNC) fraction
was obtained by density centrifugation of blood diluted 1:1
in pyrogen-free saline over Ficoll-Paque (Pharmacia
Biotech, Uppsala, Sweden). Cells were washed twice in
saline and suspended in culture medium (RPMI 1640 DM)
supplemented with gentamicin 10 g/ml, L-glutamine
10 mM and pyruvate 10 mM. The cells were counted in a
Coulter counter (Coulter Electronics, Mijdrecht, the
Netherlands) and the number was adjusted to 5 x 106
cells/ml. 
Next, 5 x 105 MNC in a 100 l volume were added to
round-bottom 96-well plates (Greiner, Alphen a/d Rijn,
the Netherlands) and incubated with either 100 l of cul-
ture medium (negative control), MDP (10 g/ml, Sigma
Chemical Co, St. Louis), purified staphylococcal peptido-
glycan (1 g/ml), or MALP2 lipopeptides (1 g/ml, EMC
Microcollections, Tübingen, Germany).
Cytokine measurements
Human IL-1 concentrations were determined by specific
radioimmunoassays as previously described.12
Statistical analysis
The experiments were performed in triplicate with blood
obtained from patients and volunteers. The differences
between groups were analysed by the Mann-Whitney U
test, and where appropriate by the Kruskal-Wallis ANOVA
test. The level of significance between groups was set at
p<0.05. The data are given as means ± SEM.
R E S U L T S
The release of IL-1 after stimulation with peptidoglycan
or MDP did not differ between healthy volunteers and
patients with Crohn’s disease who were either heterozygous
for the mutation or had no mutation (figure 1). In contrast,
patients homozygous for the mutation exhibited a strongly
decreased IL-1 synthesis in response to both peptidoglycan
or MDP (figure 1).
To investigate whether the mutated NOD2 leads to modi-
fied synergism between NOD2- and TLR2-mediated sig-
nalling, cells from the patients with the 3020insC muta-
tion were stimulated with a combination of MDP and the
lipoprotein MALP-2, a specific TLR2 agonist (figure 2).
MDP and MALP-2 appeared to have synergistic effects on
IL-1 release of normal cells; these effects were absent in
patients with the 3020insC mutation, arguing that the
3020insC mutation induces a loss-of-function phenotype. 
D I S C U S S I O N
In this paper, we demonstrate that peripheral blood
mononuclear cells of patients suffering from Crohn’s dis-
ease with the 3020insC NOD2 mutation are defective in
terms of IL-1 production when stimulated with the
NOD2 ligands MDP and peptidoglycan. These results
argue for a lack-of-function character of the mutation and
are fundamentally different from those obtained in mice
with the equivalent mutation.13
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The low IL-1 production in humans with the mutation is
in agreement with previous studies from both our labora-
tory and others demonstrating decreased production of
other proinflammatory cytokines in these patients.9-11,14
Likewise, Li et al. have shown reduced IL-1 release in
mononuclear cells from two patients with homozygous
3020insC mutation when stimulated with a combination
of MDP and TNF.15 These human studies are, however, at
odds with the increased IL-1 production in mice geneti-
cally engineered to have the same NOD2 mutation as the
human 3020insC mutation,13 which suggested a gain-of-
function phenotype of this mutation. Proponents of the
gain-of-function hypothesis have argued that the cells
from patients with the 3020inC mutation suffer from
active inflammatory disease and therefore may have down-
regulated cytokine production,16 as is commonly found in
other inflammatory conditions.17 This is, however, very
unlikely for a variety of reasons. First of all, patients with
Crohn’s disease bearing the 3020insC mutation had
lower cytokine production only after stimulation with the
NOD2 ligands peptidoglycan and MDP, but not after the
TLR2 agonist MALP-2 in this study (figure 2), or other TLR
ligands as shown in previous studies.11,14 If an inhibition
of cytokine production due to inflammation had been
present, a general downregulation of both NOD2- and
TLR-induced cytokines should have been found.
Secondly, an inflammation-driven downregulated pro-
inflammatory cytokine production tends to be associated
with an upregulated anti-inflammatory cytokine
response.17 This is not the case here: we have previously
demonstrated that the anti-inflammatory response as
exemplified by IL-10 production is strongly inhibited.10
An explanation for the increased inflammation in mice
bearing the variant NOD2 could have been the lack of
inhibitory signals on TLR2-induced cytokine release,
leading to increased cytokine production, as recently
proposed by Watanabe et al.18 Unfortunately, Maeda et al.
inappropriately tested this hypothesis by using PGN as a
putative TLR2 ligand, and stimulating cells with a combin-
ation of MDP and PGN.13 PGN is in fact the bacterial
product containing the MDP motif, and thus an NOD2
ligand. The TLR2-dependent activity of PGN has been
convincingly shown to be due to contamination with
lipoteichoic acid.19 To settle the argument whether the
lack of functional NOD2 would lead to enhanced TLR2-
mediated signals, we stimulated cells from the patients
bearing the 3020insC mutation with a combination of
MDP and the lipoprotein MALP-2, a specific TLR2 agonist
(figure 2). We have shown here that MDP and MALP-2
have synergistic effects on IL-1 release, and these effects
were absent in patients with the 3020insC mutation,
arguing that an NOD2-mediated suppression of TLR2
signals does not play an important role in patients with
Crohn’s disease.
S E P T E M B E R  2 0 0 5 ,  V O L .  6 3 ,  N O .  8
Netea, et al. NOD2 3020insC mutation and the pathogenesis of Crohn’s disease.
307
200
0
100
Controls NOD2wt NOD2het NOD2fs
**
IL
-1

 (p
g/
m
l)
MDP
PGN
Figure 1 PGN and MDP stimulation of cytokines:
requirement of NOD2 
MNC isolated from four patients with Crohn’s disease homozygous
for the 3020insC NOD2 mutation (NOD2fs), five patients hetero-
zygous for NOD2 mutations (NOD2het), five patients with the wild-
type NOD2 allele (NOD2wt) and five healthy volunteers with wild-
type NOD2 (controls), were stimulated with either 5 g/ml MDP
(solid bars) or 10 g/ml PGN (hatched bars), for 24h at 37°C. IL-1
concentrations were measured by ELISA. Data are presented as
means ± SD, and compared by Mann-Whitney U-test (*p<0.05).
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Figure 2 TLR2 and NOD2 pathways have synergistic
effects on IL-1 production 
MNC isolated from four patients with Crohn’s disease homozygous
for the 3020insC NOD2 mutation (NOD2fs), five patients heterozygous
for NOD2 mutations (NOD2het), five patients with the wild-type NOD2
allele (NOD2wt) and five healthy volunteers with wild-type NOD2
(controls), were stimulated with either 5 g/ml MDP (open bars), 
5 g/ml MALP-2 (hatched bars), or a combination of both (solid bars)
for 24h at 37°C. IL-1 concentrations were measured by ELISA. Data
are presented as means ± SD, and compared by Mann-Whitney U-test
(*p<0.05).
What could the explanation be for the apparent discrep-
ancies between 3020insC-positive Crohn’s patients and
NOD2 variant mice? Most likely, there are crucial differ-
ences between the murine and human NOD2 systems.
This may also explain why humans with NOD2 muta-
tions develop Crohn’s disease, whereas mice deficient for
NOD2 do not show any signs of inflammation.20 The
mechanisms through which the mutations in the NOD2
gene result in chronic intestinal inflammation in humans
are likely mediated by two pathways: firstly through
decreased defence against intestinal pathogens that trig-
ger the initial inflammatory reaction,21 and secondly
through loss-of-control of the intestinal inflammation due
to the defective release of anti-inflammatory cytokines
such as IL-10 and TGF.10
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